Loading clinical trials...

Propranolol for Misophonia | Clinical Trials | Clareo Health

RECRUITINGEARLY_PHASE1

Propranolol for Misophonia

Randomized, Placebo-Controlled Pilot Study of Propranolol for Treating Misophonia

NCT07271485•Bloom Mental Health, LLC

Summary

The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia. The secondary goals of this study are: 1. Determine potential predictors of response to propranolol treatment, including demographic factors, baseline symptom severity, psychometric instrument item responses, and physiological characteristics. 2. Evaluate the safety and tolerability of propranolol in individuals with misophonia.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 18-65.
•Able to complete study visit(s) in Littleton, CO.
•Able to give informed consent.
•Participant reports clinically significant misophonia symptoms, as determined by answers on the standardized "Misophonia Trigger Screening Questions for Participants" form (described separately in the protocol). Specifically, participants must demonstrate relevant misophonia trigger responses that meet pre-specified minimum severity criteria detailed on this form.
•A-MISO-S rating scale severity criterion: Participants must score at least a moderate ("2") or higher on question 2 and question 3 of the Amsterdam Misophonia Scale (A-MISO-S) at screening, since this indicates clinically meaningful misophonia severity for study eligibility.
•Able to communicate misophonic distress in writing and reasonably participate in our outpatient clinical setting, meaning able to tolerate being in this outpatient clinical setting, follow the clinic rules for all patients and guests, and respond in an understandable fashion to questions administered to them.
•Must agree to follow study clinician advice and seek additional care outside of this clinic if advised (e.g., if advised to seek help from emergency services for a potentially serious adverse reaction).
•English fluency

Exclusion Criteria

•Current use of scheduled propranolol for any condition.
•Any of the known contraindications for taking propranolol:
•cardiogenic shock
•sinus bradycardia (\<50 bpm)
•greater than first degree heart block
•BP below 90/60
•asthma / bronchial asthma that requires treatment or medication, and/or has caused clinical concerns within the last 5 years
•Other heart conditions that require ongoing medical treatment
•Participants with any of the following relative contraindications for taking propranolol:
•participants who have active anorexia, purging, or who are underweight (\<18.5 BMI)
+14 more criteria

Locations (1)

Bloom Mental Health

Littleton, Colorado, United States

Key Dates

Start Date

December 19, 2025

Primary Completion Date

December 19, 2026

Completion Date

December 19, 2026

Last Updated

December 9, 2025

Enrollment

ESTIMATED participants

Conditions

MisophoniaPropanololMisophonia Treatment

Interventions

propranolol

DRUG

Placebo

DRUG

Contacts

Bloom Mental Health Clinic

CONTACT

303-801-1776 office@bloommh.com

Digital Intervention for Adults With Misophonia: A Randomized Controlled Trial

NCT07220941

Misophonia

View study

RECRUITINGNA

Mindfulness Application Effects on Mental Health Symptoms in Children With Severe Tinnitus and Misophonia

NCT06493825

TinnitusMisophonia

View study

ACTIVE_NOT_RECRUITINGNA

Psychological Intervention for Misophonia

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 9, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions